Organization | U.O.A. di Ematologia Ospedale Molinette

U.O.A. di Ematologia Ospedale Molinette Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial

2003

NCT01148446

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2003

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 3 Trials (8)

cyclophosphamide (cytoxan) (1 trial)

doxorubicin (Doxil) (1 trial)

epirubicin (ellence) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

sargramostim (leukine) (1 trial)

vinblastine (velban) (1 trial)

vincristine (oncovin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial APIs: 8